Comparison of this fixed dose study (CALGB 9763) to the arm of the randomized Phase III study (CALGB 9342) that used paclitaxel 210 mg per square meter of BSA: Data are for cycle 1 of single-agent therapy
| . | Number of patients evaluable (enrolled) . | Mean (SD) . | Minimum . | Median . | Maximum . |
|---|---|---|---|---|---|
| CALGB 9763 Paclitaxel 360 mg | |||||
| Paclitaxel (mg/m2) | 26 (32) | 214 (34) | 164 | 203 | 300 |
| BSA (m2) | 26 (32) | 1.72 (0.26) | 1.20 | 1.77 | 2.19 |
| Nadir WBC (per μL) | 26 (32) | 3,500 (1,880) | 1,400 | 3,050 | 9,600 |
| Nadir ANC (per μL) | 26 (32) | 1,620 (1,540) | 20 | 1,020 | 6,300 |
| CALGB 9342 Paclitaxel 210 mg/m2 | |||||
| Paclitaxel (mg) | 155 (156) | 369 (37) | 289 | 370 | 546 |
| BSA (m2) | 155 (156) | 1.76 (0.18) | 1.09 | 1.76 | 2.60 |
| Nadir WBC (per μL) | 143 (156) | 2,780 (1,640) | 400 | 2,400 | 7,600 |
| Nadir ANC (per μL) | 141 (156) | 1,170 (1,190) | 20 | 730 | 5,930 |
| . | Number of patients evaluable (enrolled) . | Mean (SD) . | Minimum . | Median . | Maximum . |
|---|---|---|---|---|---|
| CALGB 9763 Paclitaxel 360 mg | |||||
| Paclitaxel (mg/m2) | 26 (32) | 214 (34) | 164 | 203 | 300 |
| BSA (m2) | 26 (32) | 1.72 (0.26) | 1.20 | 1.77 | 2.19 |
| Nadir WBC (per μL) | 26 (32) | 3,500 (1,880) | 1,400 | 3,050 | 9,600 |
| Nadir ANC (per μL) | 26 (32) | 1,620 (1,540) | 20 | 1,020 | 6,300 |
| CALGB 9342 Paclitaxel 210 mg/m2 | |||||
| Paclitaxel (mg) | 155 (156) | 369 (37) | 289 | 370 | 546 |
| BSA (m2) | 155 (156) | 1.76 (0.18) | 1.09 | 1.76 | 2.60 |
| Nadir WBC (per μL) | 143 (156) | 2,780 (1,640) | 400 | 2,400 | 7,600 |
| Nadir ANC (per μL) | 141 (156) | 1,170 (1,190) | 20 | 730 | 5,930 |
Abbreviations: BSA, body surface area; ANC, absolute neutrophil count.